Five Scientific Posters Supporting the Efficacy and Tolerability of Once-Daily Lurasidone - A New Atypical Antipsychotic

Takeda Pharmaceuticals International GmbH, headquartered in Zurich, is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As the largest pharmaceutical company in Japan and a leader in the global industry, Takeda's mission is to strive toward better health for patients worldwide through leading innovation in medicine. It has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Takeda is ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe. Takeda's commercial presence mainly covers the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management. Additional information about Takeda is available through its corporate website, http://www.takeda.com.

About Sunovion Pharmaceuticals Europe Ltd.

Sunovion Pharmaceuticals Europe headquartered in London, a wholly owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd., defines its corporate mission as "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives for people worldwide". Sunovion Europe is focused on the development and introduction of innovative medicines that improve people's health and wellbeing. The Company's focus is in Psychiatry and Neurology, including mental illness, and other disease areas of significant unmet need which require highly specialised drug development. Additional information about Sunovion Europe is available through its corporate website http://www.sunovion.eu.

This press release does not necessarily reflect the opinions of ECNP.

References

1. Murthy et al. Lurasidone for the treatment of schizophrenia: pooled analysis of short-term, placebo-controlled trials (Abstract presented at ECNP, 8 October 2013)

2. Lieberman J.A. et al. Lurasidone in the treatment of early-stage schizophrenia: a post-hoc analysis of three pooled acute treatment studies (Abstract presented at ECNP, 8 October 2013)

3. Pikalov A.et al. Comparative effectiveness of long-term treatment with atypical antipsychotics in patients with schizophrenia (Abstract presented at ECNP, 8 October 2013)

4. McEvoy J.P.et al. Switching to lurasidone in patients with schizophrenia: tolerability and effectiveness at 6 weeks and 6 months (Abstract presented at ECNP, 8 October 2013)

5. Harvey P. et al. Impact of improved insight in schizophrenia: a double-blind lurasidone and quetiapine XR study (Abstract presented at ECNP, 8 October 2013)

6. Healy D et al. Mortality in schizophrenia and related psychoses: data from two cohorts, 1875-1924 and 1994-2010. BMJ Open 2012;2:e001810.

7. Chang C-K et al. Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London. PLoS One 2011;6:e19590.

8. Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res 2011;131:101-4.

9. Tiihonen J et al. 11 year-follow up of mortality in patients with schizophrenia: a population-based cohort study (FINN11 study). Lancet 2009;374:620-7.

10. Lewis DA and Lieberman JA. Neuron 2000;28:325-34.

11. Faries DE et al. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psych 2009;9:54.

12. Tsutsumi C et al. The evolution of antipsychotic switch and polypharmacy in natural practice - A longitudinal perspective. Schizophr Res 2011;130:40-6.

13. Salize HJ et al. Cost of schizophrenia in six European countries. Schizophr Res 2009;111(1-3):70-7.

14. Mangalore R and Knapp R. Cost of schizophrenia in England. J Ment Health Policy Econ 2007;10(1):23-41.

15. Zeidler J et al. The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective. Health Econ Rev 2012;2(1):9.

Date of preparation: October 2013 Job number: EUCAN/LUR/2013-10016g

CONTACT: Takeda Media Enquiry Contacts: Kate Burd, Takeda PharmaceuticalsInternational GmbH, +44-7974-151510, kate.burd@takeda.com; Abi Thomson, RedDoor Communications, +44(0)20-8392-8049, athomson@rdcomms.com; SunovionEurope Media Enquiry contacts: Stephanie Snow, +44-7747-636-838,stephanie.snow@munroforster.com, Emily Ko, +44-7513-037066,emily.ko@munroforster.com